Advanced search    

Search: authors:"R. A. de Boer"

11 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Telemedicine in heart failure—more than nice to have?

Telemedicine in chronic diseases like heart failure is rapidly evolving and has two important goals: improving and individualising care as well as reducing costs. In this paper, we provide a critical and an updated review of the current evidence by discussing the most important trials, meta-analyses and systematic reviews. So far, evidence for the CardioMEMS device is most...

Prevalence and cardiac phenotype of patients with a phospholamban mutation

Pathogenic mutations in the phospholamban (PLN) gene may give rise to inherited cardiomyopathies due to its role in calcium homeostasis. Several PLN mutations have been identified, with the R14del mutation being the most prevalent cardiomyopathy-related mutation in the Netherlands. It is present in patients diagnosed with arrhythmogenic cardiomyopathy as well as dilated...

The fibrosis-cell death axis in heart failure

trichrome-stained cardiac tissue. Funding R. A. de Boer was supported by the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research [Vidi grant 917.13.350 ... ]. Compliance with ethical standards Conflict of interest A. Piek, R. A. de Boer and H. H. W. Silljé declare that they have no conflict of interest. References 1. Mouw JK, Ou G, Weaver VM (2014) Extracellular

Biomarkers in heart failure with preserved ejection fraction

Biomarkers are widely used and studied in heart failure. Most studies have described the utility and performance of biomarkers in sub-studies of randomised clinical trials, where the vast majority of the patients suffered from heart failure with reduced ejection fraction (HFrEF), and not with preserved ejection fraction (HFpEF). As a result, there is a scarcity of data describing...

Clinical evaluation of heart failure patients: what good are biomarkers bringing us?

R. A. de Boer 0 ) Medical Center Groningen, Department of Cardiology, University of Groningen , PO Box 30.001, 9700 RB Groningen, the Netherlands - The number of biomarker studies in heart failure

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides

AimsHeart failure with preserved ejection fraction (HFpEF) is common and its management remains difficult. B-type natriuretic peptide (BNP) levels are used to diagnose heart failure, and as an entry criterion for inclusion into trials. We investigated a population of HFpEF patients who had been randomised into a study based on clinical parameters, and compared those with low BNP...

Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?

A. M. S. Belonje R. A. de Boer A. A. Voors 0 ) Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen , Hanzeplein 1, 9700 RB Groningen, The Netherlands

Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer

R. Altena Y. M. Hummel J. Nuver A. J. Smit 0 J. D. Lefrandt 0 R. A. de Boer A. A. Voors M. P. van den Berg E. G. E. de Vries H. M. Boezen 1 J. A. Gietema E-mail: 0 Internal Medicine, Division of